ZA200710769B - Dosage regimen for prasugrel - Google Patents

Dosage regimen for prasugrel

Info

Publication number
ZA200710769B
ZA200710769B ZA200710769A ZA200710769A ZA200710769B ZA 200710769 B ZA200710769 B ZA 200710769B ZA 200710769 A ZA200710769 A ZA 200710769A ZA 200710769 A ZA200710769 A ZA 200710769A ZA 200710769 B ZA200710769 B ZA 200710769B
Authority
ZA
South Africa
Prior art keywords
prasugrel
dosage regimen
regimen
dosage
Prior art date
Application number
ZA200710769A
Other languages
English (en)
Inventor
Brandt John Thomas
Jakubowski Joseph Anthony
Weerakkody Govinda Jayanath
Farid Nagy Alphonse
Payne Christopher David
Winters Kenneth John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200710769B publication Critical patent/ZA200710769B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200710769A 2005-06-17 2007-12-11 Dosage regimen for prasugrel ZA200710769B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
ZA200710769B true ZA200710769B (en) 2009-09-30

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710769A ZA200710769B (en) 2005-06-17 2007-12-11 Dosage regimen for prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (enExample)
EP (1) EP1893205A4 (enExample)
JP (1) JP2008543853A (enExample)
KR (1) KR20080016647A (enExample)
CN (1) CN101198329A (enExample)
AU (1) AU2006259538A1 (enExample)
BR (1) BRPI0612624A2 (enExample)
CA (1) CA2612315A1 (enExample)
EA (1) EA200800075A1 (enExample)
EC (1) ECSP078014A (enExample)
GT (1) GT200600263A (enExample)
IL (1) IL187486A0 (enExample)
MA (1) MA29722B1 (enExample)
MX (1) MX2007015430A (enExample)
NO (1) NO20080244L (enExample)
TN (1) TNSN07474A1 (enExample)
WO (1) WO2006138317A2 (enExample)
ZA (1) ZA200710769B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008072532A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 貯蔵安定性が改善された医薬組成物
TWI482641B (zh) 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
CN101686681B (zh) 2007-04-27 2015-04-01 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
PL3100728T3 (pl) 2009-05-13 2020-05-18 Cydex Pharmaceuticals, Inc. Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
EP3106151A1 (en) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
KR20080021152A (ko) * 2000-07-06 2008-03-06 다이이찌 산쿄 가부시키가이샤 히드로피리딘 유도체 산부가염
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
CZ297570B6 (cs) * 2000-12-25 2007-02-07 Sankyo Company, Limited Farmaceutický prípravek obsahující 2-acetoxypyridinový derivát a aspirin, které spolu pusobí v synergickém úcinku, kit jej obsahující a pouzití
EP1660183A2 (en) * 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)

Also Published As

Publication number Publication date
JP2008543853A (ja) 2008-12-04
MA29722B1 (fr) 2008-09-01
GT200600263A (es) 2007-02-23
MX2007015430A (es) 2008-02-21
US20090156632A1 (en) 2009-06-18
BRPI0612624A2 (pt) 2016-11-29
NO20080244L (no) 2008-01-14
EA200800075A1 (ru) 2008-04-28
CN101198329A (zh) 2008-06-11
WO2006138317A2 (en) 2006-12-28
AU2006259538A1 (en) 2006-12-28
WO2006138317A3 (en) 2007-05-03
KR20080016647A (ko) 2008-02-21
ECSP078014A (es) 2008-01-23
EP1893205A2 (en) 2008-03-05
EP1893205A4 (en) 2010-06-30
IL187486A0 (en) 2008-06-05
TNSN07474A1 (en) 2009-03-17
CA2612315A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
IL251539A0 (en) Single pharmaceutical dosage form
PL2384754T3 (pl) Farmaceutyczne postacie dawkowania
IL182614A0 (en) Pharmaceutical compounds
IL187486A0 (en) Dosage regimen for prasugrel
IL181229A0 (en) Noncardiotoxic pharmaceutical compounds
ZA200803152B (en) Oramucosal pharmaceutical dosage form
GB0427455D0 (en) Dosage forms
GB0423964D0 (en) Dosage form
PL1912626T3 (pl) Postaci użytkowe o polepszonej biodostępności
GB0513984D0 (en) Dosage form
GB0616794D0 (en) Solid dosage form
GB0512453D0 (en) Dosage unit
GB0424742D0 (en) Pharmaceutical compounds
ZA200605666B (en) Solid dosage form
GB0428554D0 (en) Pharmaceutical compounds
HK1116083A (en) Dosage regimen for prasugrel
EP1744745A4 (en) PHARMACEUTICAL NITRON
GB0522989D0 (en) Dosage form
GB0411047D0 (en) Dosage form
GB0424994D0 (en) Dosage form
GB0411667D0 (en) Controlled-release dosage form
GB0411669D0 (en) Controlled-release dosage form
GB0425810D0 (en) Movable dosage indicator
AU304365S (en) Barrier bench
GB0428549D0 (en) Pharmaceutical compounds